
Johnson & Johnson
JNJAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 20, 2026 | Evercore ISI | $300.00(+16%) | $258.74 | StreetInsider | |
| Oct 16, 2026 | Wells Fargo | Larry Biegelsen | $287.00(+13%) | $253.28 | TheFly |
| Oct 15, 2026 | Bernstein | Lee Hambright | $270.00(+4%) | $259.85 | StreetInsider |
| Oct 14, 2026 | RBC Capital | $280.00(+11%) | $251.68 | TheFly | |
| Oct 14, 2026 | Leerink Partners | $272.00(+8%) | $251.75 | TheFly | |
| Oct 14, 2026 | Wells Fargo | Larry Biegelsen | $275.00(+11%) | $248.61 | TheFly |
| Oct 14, 2026 | UBS | $270.00(+9%) | $248.61 | TheFly | |
| Oct 6, 2026 | RBC Capital | Shagun Singh | $290.00(+15%) | $252.93 | StreetInsider |
| Sep 29, 2026 | New Street | $278.00(+2%) | $271.95 | StreetInsider | |
| Sep 10, 2026 | HSBC | $320.00(+20%) | $267.08 | TheFly | |
| Sep 2, 2026 | UBS | $320.00(+18%) | $271.19 | TheFly | |
| Aug 6, 2026 | Guggenheim | $287.00(+11%) | $257.59 | TheFly | |
| Aug 3, 2026 | Raymond James | $280.00(+10%) | $254.45 | StreetInsider | |
| Aug 3, 2026 | Wells Fargo | $282.00(+10%) | $256.35 | TheFly | |
| Jul 29, 2026 | Argus Research | David Toung | $300.00(+13%) | $266.13 | TheFly |
| Jul 16, 2026 | Johnson Rice | Ilya Zubkov | $280.00(+12%) | $249.75 | TheFly |
| Jul 16, 2026 | Scotiabank | $305.00(+23%) | $248.95 | TheFly | |
| Jul 16, 2026 | Raymond James | $265.00(+6%) | $250.50 | TheFly | |
| Jul 16, 2026 | Johnson Rice | $261.00(+4%) | $250.49 | StreetInsider | |
| Jul 16, 2026 | Goldman Sachs | $282.00(+14%) | $247.02 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wells Fargo | maintain | Overweight | Oct 16, 2026 |
| Morgan Stanley | maintain | Overweight | Oct 15, 2026 |
| Leerink Partners | maintain | Outperform | Oct 14, 2026 |
| RBC Capital | maintain | Outperform | Oct 14, 2026 |
| Wells Fargo | maintain | Overweight | Oct 14, 2026 |
| Guggenheim | maintain | Buy | Oct 7, 2026 |
| RBC Capital | maintain | Outperform | Oct 6, 2026 |
| Citigroup | maintain | Buy | Oct 5, 2026 |
| JP Morgan | maintain | Neutral | Sep 29, 2026 |
| HSBC | maintain | Buy | Sep 10, 2026 |
| UBS | maintain | Buy | Sep 2, 2026 |
| Guggenheim | maintain | Buy | Aug 6, 2026 |
| Wells Fargo | maintain | Overweight | Aug 3, 2026 |
| Guggenheim | maintain | Buy | Jul 17, 2026 |
| Morgan Stanley | maintain | Overweight | Jul 16, 2026 |
| RBC Capital | maintain | Outperform | Jul 16, 2026 |
| Raymond James | maintain | Outperform | Jul 16, 2026 |
| Wells Fargo | maintain | Overweight | Jul 16, 2026 |
| RBC Capital | maintain | Outperform | Jul 13, 2026 |
| TD Cowen | maintain | Buy | Jul 13, 2026 |
| B of A Securities | maintain | Neutral | Jul 10, 2026 |
| Citigroup | maintain | Buy | Jul 8, 2026 |
| Morgan Stanley | maintain | Overweight | Jul 8, 2026 |
| Guggenheim | maintain | Buy | Jun 26, 2026 |
| Leerink Partners | upgrade | Market Perform →Outperform | May 13, 2026 |
Earnings History
Next report: Jan 26, 2027 · EPS est. $2.91| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 13, 2026 | $2.59 | $2.52 | $25.40B | $25.38B |
| Jul 15, 2026 | $2.90 | $2.85 | $25.31B | $25.06B |
| Apr 14, 2026 | $2.70 | $2.68 | $24.06B | $23.61B |
| Jan 21, 2026 | $2.46 | $2.46 | $24.56B | $24.15B |
| Oct 14, 2025 | $2.80 | $2.76 | $23.99B | $23.76B |
| Jul 16, 2025 | $2.77 | $2.68 | $23.74B | $22.85B |
| Apr 15, 2025 | $2.77 | $2.58 | $21.89B | $21.56B |
| Jan 22, 2025 | $2.04 | $1.99 | $22.52B | $22.43B |
News
Johnson and Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerPR NewswireNEW BRUNSW
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer Deep and sustained PSA responses observed with every-six-week dosing, with 73% (11 of 15 patients) achieving reductions of at least 50% and nearly half achieving reductions of at least 90% in Phase 1 study With an encouraging safety profile, findings show potential for outpatient dosing as the…
A quiet Sunday is a good time to look past the noise and study what actually lands in your account: cash dividends supported by real cash flow.
New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva production b in more than twice as many patients on nipocalimab compared to placebo c Two Phase 3 studies are ongoing, evaluating nipocalimab in Sjögren's disease including these measures critical to patients NEW BRUNSWICK, N.J.…
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill NEW BRUNSWICK, N.J., Nov. 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive resul…
J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial
Alps Advisors Inc. reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 16.0% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 177,499 shares of the company's stock after selling 33,788 shares during the quarter. Alps Advisors Inc.'s
Alps Advisors Inc. reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 16.0% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 177,499 shares of the company's stock after selling 33,788 shares during the quarter. Alps Advisors Inc.'s
Three words sum up this historically successful investing strategy.
A guaranteed bank rate sounds safe until you weigh what it can't do.
Some companies will perform pretty well regardless of whether or not interest rates rise.
J&J's Innovative Medicine sees a 7.7% rise in Q3 sales to $16.76 billion, as blockbuster drugs and new launches offset generic headwinds.
When profits dip, lenders get paid first and the dividend is usually what gets cut. Four household names have raised their payouts year after year, and one of them holds a credit rating almost no other U.S. company can match.
Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory hearing that could change its income story.
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First advancement in the second-line treatment setting for recurrent or metastatic head and neck cancer in a decade, bringing a new subcutaneous option to patients with significant unmet need2-3 Extending its well-established, dual-targeted benefit beyond lung cancer, RYBREVANT FASPRO™ targets both EGFR and MET pathways…
Retirees chasing big yields often get burned, so these four companies took a different route: raising payouts every year for over six decades. Which one has the most cushion, and which carries a risk that could rattle your portfolio?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Bayer Aktiengesellschaft (BAYRY) and Johnson & Johnson (JNJ). But which of these two stocks is more attractive to value investors?
They have both outperformed the broader equity market over the long run.
Some stocks are worth holding for decades, and they usually have one thing in common: a dividend that went up every year through recessions, rate shocks and bear markets.